Mark Agulnik MD
Sarcoma
Professor of Clinical Medicine Vice Chair for Faculty Development, Department of Medicine Section Chief of Sarcoma and Melanoma USC Norris Comprehensive Cancer Center; Keck School of Medicine of USC
Join to View Full Profile
Keck Medicine of USC1441 East Lake Avenue, Suite NTT 3440Los Angeles, CA 90033
Phone+1 323-865-3000
Fax+1 323-865-0061
Dr. Agulnik is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Mark Agulnik, MD, is a Sarcoma Oncology specialist in Los Angeles. He received his MD from McGill University. He is a Professor of Medicine at Keck USC. He has a proven track record in Sarcoma Oncology, has been part of numerous clinical trials and has multiple publications. He is the recipient of the Meaninful Use Stage 1 Certification and is recognized as a Super Doctor by SuperDoctors.com.
Education & Training
University of TorontoClinical Research Fellowship, 2004 - 2006
University of Illinois College of Medicine at ChicagoFellowship, Hematology and Medical Oncology, 2001 - 2004- Dalhousie UniversityResidency, 1999 - 2001
- Dalhousie UniversityInternship, 1998 - 1999
McGill University Faculty of MedicineClass of 1998
Certifications & Licensure
CA State Medical License 2020 - 2026
IL State Medical License 2004 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
The Royal College of Physicians and Surgeons of CanadaInternal Medicine/Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012-2017
- CMS Meaningful Use Stage 1 Certification PowerChart, Cerner Corporation, 2012-2017
Clinical Trials
- Bevacizumab in Treating Patients With Angiosarcoma Start of enrollment: 2005 Oct 01
- Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2008 Aug 08
- Everolimus Versus Placebo in Head and Neck Cancer Start of enrollment: 2010 Apr 01
Publications & Presentations
PubMed
- Chondrosarcoma: Clinical behavior, molecular mechanisms, and emerging therapeutic strategies.Mark Agulnik, Breelyn A Wilky, Steven W Thorpe, Lee M Zuckerman
Critical Reviews in Oncology/hematology. 2026-02-01 - Management of tenosynovial giant cell tumor: approved and investigational therapies.Alexander P Conway, Andrew Lim, Brian C Schulte, Mark Agulnik
Expert Review of Anticancer Therapy. 2026-01-24 - Cabozantinib and temozolomide in patients with unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas: a multicentre, single-arm, lead-in phase 2 trial.Varun Monga, Scott Okuno, Brian Van Tine, Seth M Pollack, Mia Weiss
The Lancet. Oncology. 2026-01-16
Press Mentions
Sarcoma Trial for New Cancer Treatment Begins at City of Hope in Los AngelesMarch 8th, 2022- Rafael Pharmaceuticals Announces APOLLO613 Phase I/II Clinical Trial of CPI-613® (Devimistat) in Combination with Hydroxychloroquine in Patients with Relapsed Clear Cell Sarcoma Begins Enrollment at City of Hope in Duarte, CalifSeptember 27th, 2021
Experts Explain the Staging and Treatment of cSCCNovember 28th, 2019
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
